Teacher Retirement System of Texas boosted its position in Insmed Incorporated (NASDAQ:INSM – Get Rating) by 3.6% during the fourth quarter, HoldingsChannel reports. The fund owned 40,586 shares of the biopharmaceutical company’s stock after buying an additional 1,417 shares during the quarter. Teacher Retirement System of Texas’ holdings in Insmed were worth $811,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Almanack Investment Partners LLC. purchased a new stake in Insmed in the third quarter worth approximately $25,000. CWM LLC boosted its holdings in shares of Insmed by 645.9% during the 4th quarter. CWM LLC now owns 1,544 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,337 shares in the last quarter. Quantbot Technologies LP grew its holdings in Insmed by 2,170.4% in the second quarter. Quantbot Technologies LP now owns 2,452 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 2,344 shares during the period. Assetmark Inc. increased its position in Insmed by 110.3% during the 4th quarter. Assetmark Inc. now owns 2,536 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 1,330 shares in the last quarter. Finally, Point72 Hong Kong Ltd raised its position in shares of Insmed by 42.3% in the 3rd quarter. Point72 Hong Kong Ltd now owns 3,856 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,146 shares during the last quarter. 92.83% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
INSM has been the subject of a number of recent research reports. StockNews.com raised shares of Insmed from a “sell” rating to a “hold” rating in a research report on Thursday. Credit Suisse Group reiterated an “outperform” rating and issued a $46.00 price target on shares of Insmed in a research note on Friday, February 24th. HC Wainwright restated a “buy” rating and set a $52.00 price objective on shares of Insmed in a research report on Friday, February 24th. Finally, Cantor Fitzgerald lowered their price target on shares of Insmed from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Friday, February 24th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.33.
Insmed Price Performance
Insmed (NASDAQ:INSM – Get Rating) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.09). The business had revenue of $65.20 million during the quarter, compared to analyst estimates of $63.93 million. Insmed had a negative net margin of 212.33% and a negative return on equity of 3,789.32%. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. On average, research analysts forecast that Insmed Incorporated will post -4.53 earnings per share for the current year.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
See Also
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- A 7% Yield and 50% Upside?! Wall Street Digs Rio Tinto
- FuelCell Is Back To Realistic Valuation
- MarketBeat Week in Review – 6/4 – 6/9
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM – Get Rating).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
